Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.36 |
| ▸ | EDNRB | P24530 | 1/20 | 0.35 |
| ▸ | EDNRA | P25101 | 1/20 | 0.35 |
| ▸ | KIF11 | P52732 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 4/20 | 0.32 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 3/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30685518 | 1.00 | HDAC9 (0.36) | HDAC9EDNRBEDNRAKIF11MEN1 | |
| SCHEMBL1404157 | 0.81 | HDAC9 (0.41) | HDAC9EDNRBEDNRAKIF11MEN1 | |
| SCHEMBL30685517 | 0.81 | HDAC9 (0.41) | HDAC9EDNRBEDNRAKIF11MEN1 | |
| SCHEMBL1404156 | 0.81 | HDAC9 (0.41) | HDAC9EDNRBEDNRAKIF11MEN1 | |
| SCHEMBL1404158 | 0.81 | HDAC9 (0.41) | HDAC9EDNRBEDNRAKIF11MEN1 | |
| SCHEMBL29271794 | 0.81 | CHRNA7 (0.36) | EDNRBEDNRAKIF11AKR1B1OPRM1 | |
| SCHEMBL30965948 | 0.81 | CHRNA7 (0.36) | EDNRBEDNRAKIF11AKR1B1OPRM1 | |
| SCHEMBL27956103 | 0.81 | HDAC9 (0.43) | HDAC9EDNRBEDNRAKIF11MEN1 | |
| SCHEMBL3732088 | 0.81 | HDAC9 (0.43) | HDAC9EDNRBEDNRAKIF11MEN1 | |
| SCHEMBL28389144 | 0.80 | OPRM1 (0.50) | EDNRBEDNRAOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111051287-B | Method for producing organic compound | 株式会社钟化 | 2023-10-03 | — | — | CN | disclosed |
| US-11161820-B2 | Process for producing organic compound | KANEKA CORPORATION (JP) | 2021-11-02 | — | — | US | disclosed |
| EP-3680235-A1 | ORGANIC COMPOUND PRODUCTION METHOD | Kaneka Corporation (JP) | 2020-07-15 | — | — | EP | disclosed |
| US-20200207717-A1 | PROCESS FOR PRODUCING ORGANIC COMPOUND | KANEKA CORPORATION (JP) | 2020-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11161820-B2 | Process for producing organic compound | RPN2, RPN1, DAD1 | HDAC9 4867/4885EDNRB 2034/4885EDNRA 3008/4885 |
| US-20200207717-A1 | PROCESS FOR PRODUCING ORGANIC COMPOUND | RPN2, RPN1, DAD1 | HDAC9 4867/4885EDNRB 2034/4885EDNRA 3008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.